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Synthesis
General methods: Melting points were determined with a Büchi Melting Point B-540 apparatus.
1 H NMR and 13 C NMR spectra were recorded on Brucker ARX 250, Brucker DRX 300, or Brucker DRX 500 spectrometers by using CDCl 3 if not otherwise indicated. Chemical shifts (δ) are expressed in ppm relative to TMS. Multiplicity is indicated as s (singlet), d (doublet), t (triplet), m (multiplet), bs (broad singlet), and cm (centered multiplet). H ar stands for an aromatic proton in 1H NMR. C q indicates a quaternary carbon in the 13 C NMR assignation. J values are given in Hz.
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F NMR was performed using 1,2-difluorobenzene as external standard (δ= -139.0 ppm). Electron Impact (EI) mass spectra were recorded at 70 eV on Jeol JMS-700 and Finnigan TSQ 700 spectrometers at the Department of Organic Chemistry at the Ruprecht Karls University, Heidelberg. Elemental analyses were carried out in the Microanalysis Laboratory of the Faculty of Chemistry at the Ruprecht Karls University, Heidelberg. Analytical thin layer chromatography (TLC) was performed on pre-coated silica gel plates Polygram ® SIL G/UV254 from Machery-Nagel, and silica gel G60 from Macherey-Nagel (230-400 mesh) was used for flash column chromatography. General procedure 1: The bromonaphthalene (1.0 equiv.) was placed in an argon-flushed flask. Dry THF was added, and the mixture was cooled to -78 °C. BuLi (1.1 equiv.) was added dropwise, and the mixture was stirred for 10 min at -78 °C. Then, the benzoyl chloride (1.1 equiv.) was added under stirring, and the reaction mixture was stirred at -78 °C for 30 min. The reaction mixture was then allowed to warm to RT. The mixture was poured into a 20 mL 1:1 mixture of diluted HCl : saturated NaCl and it was extracted twice with 20 mL Et 2 O. The organic phase was dried over MgSO 4 and evaporated. The resulting oil was purified through flash chromatography.
(1,4-dimethoxy-3-methylnaphthalen-2-yl)(2-fluoro-4-(trifluoromethyl)phenyl)methanone (5c). Yield = 42% 2-bromo-1,4-dimethoxy-3-methylnaphthalene (300 mg, 1.07 mmol) and commercially available 2-fluoro-4-trifluoromethyl-benzoyl chloride (265 mg, 1.17 mmol) were treated according to general procedure 1. The resulting yellow oil was purified through flash chromatography (cyclohexane:EtOAc 10:1). The product 5c was obtained as yellow oil (175 A solution of dimethoxynaphthalene (1.0 equiv.) in dry DCM was cooled to 0 °C and kept stirring for 30 min. Then, BBr 3 (1.0 equiv., 1 M in DCM) was added dropwise to the solution, and the reaction mixture was stirred at 0 °C for 2 h (TLC control). The reaction mixture was quenched with MeOH. Saturated NaCl was added to the mixture, which was extracted three times with DCM and twice with EtOAc. The organic layers were combined, dried over MgSO 4 , and evaporated. Yield = 68% (1,4-dimethoxy-3-methylnaphthalen-2-yl)(2-fluoro-4-(trifluoromethyl)phenyl)methanone 5c (230 mg, 0.60 mmol) was used as a starting material and treated according to general procedure 2. The resulting yellow oil was purified through flash chromatography (DCM:cyclohexane 1:1). (1,4-dimethoxy-3-methylnaphthalen-2-yl)(2-fluoro-4-(trifluoromethyl)phenyl)methanone 5c (250 mg, 0.64 mmol) dissolved in 40 mL DCM was cooled to 0 °C and kept stirring for 30 min. Pure BBr 3 (61 µL, 0.64 mmol, 1.0 equiv.) was added dropwise to the solution, and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was quenched with 60 mL MeOH. Saturated NaCl was added to the mixture, and it was extracted with DCM (2 x 50 mL). The organic layer wad dried over MgSO 4 and evaporated to give 500 mg of a red-orange solid. The red-orange residue was recrystallized in 10 mL of a 10:1 cyclohexane:EtOAc mixture. Yield = 63%, Overall yield after 6 steps from menadione: 26% (via 3c*) (1,4-dihydroxy-3-methylnaphthalen-2-yl)(2-fluoro-4-(trifluoromethyl)phenyl)methanone 3c* (100 mg, 0.275 mmol) was used as a starting material and treated according to general procedure 3. The resulting red-orange solid (90 mg) was recrystallized in 5 mL cyclohexane:EtOAc:acetone, 10: Overall Yield = 64% (5 steps)
5-methoxy-6-methyl-11-(trifluoromethyl)-7H-benzo[c]xanthen-7-one (7i).
The synthesis of 3c-MOM and benzoxanthone 4c (49% yield in 6 steps from menadione) via 3c-MOM will be described separately, along with all related data acquired in electro-and physico-chemistry.
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Physico-Biochemical Studies
The experimental conditions related to (i) the spectrophotometric titration of haematin π-π dimer by the substrates, (ii) the β-haematin inhibition assay, and (iii) the metHb reduction assay, are available in ref. 1.
Materials and Methods:
Distilled water was purified by passing it through a mixed bed of ionexchanger (Bioblock Scientific R3-83002, M3-83006) and activated carbon (Bioblock Scientific ORC-83005). DMSO (E. Merck, Uvasol, for spectroscopy or Sigma, Bioreagent, for molecular biology), acetonitrile (E. Merck Uvasol, for spectroscopy), and chloroquine (Sigma, diphosphate salt) were obtained from commercial suppliers and used without further purification. Haematin (Fe III PPIX(OH)) solution was prepared from haemin equine Type III (Fe III PPIXCl, Sigma-Aldrich) and 50% aqueous ammonia (ESI-MS CID experiments) vigorously stirred at room temperature (RT) for 1 h. Stock solutions (DMSO) of the substrates (1c-4c, CQ, AQ) for the different assays were freshly prepared in Eppendorf tubes just before the experiments. All stock solutions were prepared using an AG 245 Mettler Toledo analytical balance. Electrochemistry: Cyclic voltammetry (CV) and square wave voltammetry (SWV) experiments of menadione, benzylMD 1c, benzoylMD 2c, and benzoxanthones 4c and 7i were performed on a Voltalab 50 potentiostat/galvanostat (Radiometer Analytical) controlled by the Voltamaster 4 electrochemical software at different scan rates and at room temperature (25 ± 1 °C). A conventional three-electrode cell (10 mL) was employed with a glassy carbon disk from spectroscopic graphite rods set into a Teflon tube (s = 0.071 cm 2 ) as a working electrode, a Pt wire as a counter electrode, and KCl (3.5 M)/Ag/AgCl reference electrode (+205 mV vs NHE).
3 Prior to a voltammetry experiment, the working electrode was mechanically polished with and without alumina suspension (ESCIL, 0.3 µm) on a silicon carbide paper (800/2400 grit) followed by sonication in Milli-Q water. The menadione, benzylMD 1c, benzoylMD 2c, and benzoxanthones 4c or 7i solutions (~1 mM) were prepared with spectroscopic-grade DMSO (E. Merck, Uvasol, for spectroscopy or Sigma, Bioreagent, for molecular biology) as solvent and with 0.1 M tetrabutylammonium hexafluorophosphate (NBu 4 PF 6 ) as electrolyte support. All the solutions were carefully deoxygenated with argon for 30 min (Sigma Oxiclear cartridge). The electrode was installed into the voltammetric cell along with the platinum wire counter electrode and the reference. The substrates were then introduced (~ 10 mL), and the solution was again purged for 10 min with argon (Sigma Oxiclear cartridge) before the voltammetry experiment was initiated. Voltammograms were generally recorded at a sweep rate of 200 mV s -1 . The redox potentials E 1/2 were determined from the corresponding oxidation and reduction potentials. All potential measurements were referred to a saturated calomel electrode (SCE).
MetHb reduction coupled assay with GR/NADPH: hGR and PfGR were purified and quantified as described previously.
4,5 A 1 mL solution containing metHb (8 µM final), the drug (40 µM final), NADPH (120 µM final) was incubated at 25 °C in GR buffer. hGR or PfGR was then added (100 nM final) and the reaction followed by UV-vis absorption spectrophotometry between 300 and 700 nm. Different controls showing the essential requirement of the benzoylMD 2c, in the presence of GSH or GSSG are shown in Fig. S7 .
Continuous metHb redox assay in the presence of the GR/NADPH system: Stock solutions of 2 mM of the drugs in DMSO were freshly prepared. Solutions of 0.8 mM metHb in water and 16 mM NADPH in water were prepared and kept at 0 °C during the experiment. In a Hellma optical cell (l = 0.5 cm), 878 µL of the hGR buffer, 40 µL of the metHb solution (0.8 mM), 20 µL of the drug solution (2 mM), and 30 µL of the NADPH solution (16 mM) were introduced at 25 °C (Lauda E200/O11 thermostat and a Huber Minichiller cooler) for 3-5 min. Then, 32 µL of the GR stock solution (12.5 µM) was added. After the redox cycling had stopped, 30 µL of a 16 mM NADPH solution was added. The reaction was monitored by UV-vis absorption spectrophotometry on a Cary 50 or Cary 300 spectrophotometer with the scanning kinetics method. A spectrum was measured every 10 min or 30 min, depending on the experiment, between 300 and 700 nm for the stated period of time. The kinetic data were processed with the Specfit program.
Procedure for ferrylHb determination via sulfHb: Several 1 mL samples of the metHb reduction reaction were prepared at the same time in separate Eppendorf vials and tempered at 25 °C according to the continuous metHb redox assay above. The essay was monitored every 30 min by UV-Vis spectrophotometry for 7 hours ( fig. 3b and fig. S8a,c) . Every hour one new sample (500 µL) was taken and transferred into a cuvette [Hellma optical cell (l = 1 cm)]. This cuvette was placed in another spectrophotometer and the reaction mixture was reacted with 10 µL of catalase (EC 1.11.1.6, 61 Units final as defined by Sigma) for 30 seconds to destroy excess of H 2 O 2 and then with 5 µL of aq. Na 2 S solution (200 mM stock solution). Spectra were recorded every min for a period of 20 min to ensure equilibration. The characteristic peak for sulfHb at 620 nm was integrated to determine its area using Origin as data processing program (Fig. S8b ).
Parasitology and cell biology studies
Chemicals
ML276 or (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b]
[1,4]thiazine-6-carboxamide) was provided by the laboratory of Pr. Katja Becker. CB83 or N-(4-hydroxy-1-naphthalenyl)-2,5-dimethyl-benzenesulfonamide was purchased from Interchim (Montluçon, France). The compounds diamide or N,N,N′,N′-tetramethylazodicarboxamide, phenylhydrazine, nicotinamide, 6-aminonicotinamide, desferrioxamine (DFO) and epigallocatechin-3-gallate (EGCG) were purchased from Sigma-Aldrich. Stock solutions of compounds were prepared in pure water (nicotinamide, DFO, EGCG) or in DMSO (1c, P_TM101 (or compound 7a in ref. 6), 4c, ML276, CB83 and 6-aminonicotinamide). All stock solutions were stored in aliquots at -20 °C.
P. falciparum strains and cultures:
In vitro studies using living P. falciparum blood stage parasites were performed in three different laboratories [laboratory A = Department of Infectiology, University of Heidelberg, Germany; laboratory B = Museum National d'Histoire Naturelle, Paris, France; laboratory C = Interdisciplinary Research Centre, Justus Liebig Giessen University, Germany], herein after referred to as laboratory A, B or C. Cultures of P. falciparum strain 3D7 (chloroquine sensitive) or strain Dd2 (chloroquine resistant) were maintained according to standard protocols 7 under individual routine culture conditions as previously described for laboratory A, 8 laboratory B, 9 and laboratory C.
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Growth inhibition assays: Antimalarial activities (presented as IC 50 values (Table 2 ) on the chloroquine sensitive 3D7 strain and the CQ resistant Dd2 strain) of compounds 1c, 3c, 4c, 7c, 7i, 7j, and CQ were determined in laboratory C by the [ 3 H] hypoxanthine incorporation assay, 11 as described.
In vitro drug interaction studies: In vitro interactions between the benzylMD 1c and derivatives (P_TM101, 4c) or experimental molecules (DFO, ML276, EGCG, CB83) were investigated using the fractional inhibitory concentration (FIC) index described in the established fixed-ratio isobologram method, 12 in which a two-dimensional array of serial concentrations of test compounds is used to demonstrate that paired combinations of agents can exert inhibitory effects that are higher (synergy; Ʃ FIC 50 < 1.0) or lower (antagonism; Ʃ FIC 50 > 1.0) than the sum of their effects alone. First, to assess the method, a paired combination of two separate 1c stock solutions used at different ratio was tested and revealed a clear additive effect (Ʃ FIC 50 = 0.98 ± 0.02), as expected. These assays were performed in laboratory A (DFO, EGCG, P_TM101, 4c) or in laboratory B (ML276, CB83). Briefly, an asynchronous blood stage culture of P. falciparum strain 3D7 was incubated for 48 h in the presence of decreasing drug concentrations in a microtiter plate (1% parasitemia, 1.5-2 % haematocrit). Drugs were applied alone and in combination at fixed concentration ratios (ratio A : B (v:v) = 1:4, 2:3, (2.5:2.5), 3:2, 4:1) and analysed in threefold serial dilutions. IC 50 values of drugs A and B alone were determined on the same plate to ensure accurate calculation of drug interactions. Also, the lead parent benzylMD 1c was combined to itself (control assay of additive) to estimate the impact of experimental errors introduced by handling. Parasite growth was assessed in laboratory A using a SYBRgreen protocol,8 and in laboratory B by the [ 3 H] hypoxanthine incorporation assay.9 Arithmetical and graphical analyses of results were performed. For arithmetical analysis, the fractional inhibitory concentration (FIC) of each drug in a given combination was calculated according to the following definitions: FIC (A) = IC 50 of A in combination / IC 50 of A alone and FIC (B) = IC 50 of B in combination /IC 50 of B alone. The sum of FIC (A) and FIC (B) (∑ FIC) was established for each combination and then the mean value of the four ∑ FICs was calculated. A mean ∑ FIC = 1 was assumed to reflect an additive effect or indifferent interaction, a mean ∑ FIC < 1 a synergistic interaction and a mean ∑ FIC > 1 an antagonistic interaction between the tested drugs. The graphical presentation (isobolograms) was established by plotting pairs of FIC values of drug A and drug B for each combination. The fixed-ratio isobologram method was not applicable for nicotinamide or 6-aminonicotinamide because it was not possible to determine their IC 50 values due to poor growth inhibition activities and poor solubility of the compounds. Though to explore the in vitro interactions, the IC 50 values of lead benzylMD 1c were determined in the presence of a fixed dose of nicotinamide or 6-aminonicotinamide, which showed no inhibition of parasitic growth when applied alone. IC 50 values were determined in laboratory A using a SYBRgreen protocol.
In vitro interaction of the lead parent benzylMD 1c with the hGrx1-roGFP2 protein:
The recombinant hGrx1-roGFP2 protein was heterologously overexpressed and prepared for measurements as described. 10 In short, a stock solution of 5 mM 1c in DSMO was diluted to 500 µM, 50 µM and 5 µM in a standard reaction buffer (as described) and mixed with 1.25 µM of purified and reduced hGrx1-roGFP2 protein to final concentrations of 1 mM, 100 µM, 10 µM, and 1 µM in a 96-well plate. After 15 min, 4 h, and 24 h incubation at room temperature, the emission of hGrx1-roGFP2 (510 nm) was measured after excitation at 405 and 480 nm in a plate reader (M200, Tecan) with gains set to 75 and 60, respectively. We calculated the ratio of the emission (405/480 nm) and plotted it against time or concentration of antimalarial drugs. In addition, an excitation spectrum was scanned from 340-504 nm with emission at 530 nm after 15 min, 4 h, and 24 h incubation. To exclude a direct interaction between 1c and the redox probe, the inhibitor was first incubated with the isolated recombinant hGrx1-roGFP2 protein. After 5 min only the highest concentration of compound 1c tested (1 mM corresponding to 20,000 x IC 50 , which is pharmacologically not relevant), led to a 405/488 nm ratio increase from 0.57 to 0.80 (1.4-fold change). In comparison, 1 mM of the oxidizing agent diamide (which served as positive control) led to a ratio increase from 0.57 to 3.8 (6.6-fold change) (Fig. S10a) . This result was supported by spectral analyses (Fig. S10d) . After 4 h and 24 h incubation with 1 mM 1c the 405/488 nm ratios increased to 2.3 and 2.6, respectively, which was partially induced by the solvent DMSO at 24h (Figs. S10b and S10c), while lower concentrations showed hardly any effects. Again, these results were supported by spectral analyses (Figs. S10e and S10f). In summary, a direct interaction between compound 1c and the redox sensor influencing the results at pharmacologically relevant concentrations could be excluded.
Imaging of the glutathione redox state in Plasmodium after 1c treatment: Cloning the glutathione redox sensor hGrx1-roGFP2 as well as cultivation, sorbitol synchronization, and transfection of the chloroquine-sensitive P. falciparum 3D7 strain were carried out in laboratory C as described. 10 P. falciparum 3D7 hGrx1-roGFP2 -parasitized RBCs were enriched and prepared for microscopy as described. Compound 1c was freshly dissolved in DMSO [5 mM] and diluted in pre-warmed (37 °C) Ringer's solution. Immediately treatment 20 mM N-ethylmaleimide was added to the cells to non-reversibly block sulfhydryls. Microscopy was carried out as described. 10 In brief, we excited hGrx1-roGFP2 at 405 nm and at 488 nm and detected emissions at 500-530 nm. Images were analysed by a custom written MatLaB (The MathWorks, www.mathwork.de) analysis suite (M.D. Fricker, Dept. Plant Sciences, Oxford). Images were corrected for autofluorescence bleeding into the 405 nm channel, the background for each channel was subtracted and the 405/488 nm ratio was computed on a pixel-bypixel basis. The region of interest was a well-defined cytosolic area of morphologically intact parasites.
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Cultivation and separation of ring-parasitized RBC and control non-parasitized RBC, treated of not with the lead parent benzylMD 1c and phenylhydrazine: P. falciparum parasites (Palo Alto strain, Mycoplasma-free) were cultivated in freshly drawn normal RBCs at 2% haematocrit and synchronized as described. 13 Briefly, schizont stage parasitized normal RBCs (parasitemia > 95%) were mixed for invasion with washed normal RBCs and kept in growth medium (RPMI 1640, containing 25 mM Hepes, 30 mM glucose, 2 mM glutamine, 0.02 mM adenine, 24 mM NaHCO 3 , 32 µg/l gentamicin, and 10% A + decomplemented human plasma). After 19 h incubation in a humidified CO 2 /air incubator, the ring-enriched fraction was separated on and collected from a discontinuous 40/80/90% Percoll gradient (Sigma) containing mannitol (6% wt/vol). After 19 h incubation rings were enriched to approx. > 70% by the above procedure. Parasitemia and parasite morphology were assessed by light microscopy after Diff-Quik ® Fix staining (Medion Diagnostics GmbH, Düdingen, Switzerland). Non-parasitized control RBCs were incubated and treated in a similar way without schizont inoculation at time 0. Ringparasitized and non-parasitized RBCs, treated or not with the lead benzylMD 1c 500 nM (10-fold IC 50 ), 2.5 µM (50-fold IC 50 ) or 5.0 µM (100-fold IC 50 ) or supplemented with 2.0 mM phenylhydrazine, were suspended at 30% haematocrit in HANKS solution with 5.5 mM glucose, pH 7.45, and incubated at 37.5 °C. After 4 h incubation, hypotonic ghosts were prepared from the ring-enriched fraction (approx. 70% parasitemia) and from the non-parasitized control RBCs.
Quantification of membrane-bound haemichromes in ghosts prepared from non-parasitized and ring-parasitized RBCs, and from non-parasitized G6PD-deficient RBCs: Haem bound to the cytoplasmic face of the membrane as insoluble haemichromes was analysed in the hypotonic ghosts 14 prepared under non-reducing conditions in the presence of Complete ® protease inhibitor and Trolox ((±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, Sigma, 100 µM final) cocktail from the ring-enriched fraction (approx. 70% parasitemia) and from the non-parasitized control RBCs. 15 Every ghost preparation was divided into two aliquots. A first aliquot of 15 µL ghosts was solubilized for 3 h at 4 ºC in 1 mL of 0.1 N NaOH containing 3 mM EDTA and 0.05% (vol/vol) Triton X100 to quantify the total haem content (haemoglobin + insoluble haemichromes). A second aliquot of 15 µL ghosts was solubilized for 1 h at room temperature in 1 mL of PBS containing 3 mM EDTA and 0.05% (vol/vol) Triton X100 and used to quantify haemoglobin. Haem from both ghost aliquots was quantified by measuring the haem-dependent, luminol-enhanced luminescence as described. 16 Each luminescence measurement (5 µL aliquots) was repeated 3-4 times. Inter-measurement variability never exceeded 2-3%. The haemichrome content was calculated from the difference between total haem and haemoglobin haem. Haemichrome haem was the major component of total haem in control rings (88% of total haem), while membrane-bound haemoglobin was a minor fraction of total haem. Additional experiments using the same method described before were performed with non-parasitized G6PD-deficient RBC (Mediterranean variant with < 1% of normal enzyme activity) characterized by high sensitivity towards oxidants like diamide and phenylhydrazine. . MetHb (32 µM), benzoylMD 2c (40 µM), NADPH (480 µM), SOD (7.2 U/mL) PfGR (400 nM), 25 °C; red curve=start (0 h), blue curve=end (7 h); (b) the indirect determination of ferrylHb: example after 1 h; the spectrum of sulfHb obtained after the addition of Na 2 S with the integration of peak at 620 nm; (c) Solvent: water (47 mM phosphate buffer pH 6.9 + 1 mM EDTA + 200 mM KCl). MetHb (32 µM), benzoylMD 2c (40 µM), NADPH (480 µM), PfGR (400 nM), 25 °C; red curve=start (0 h), blue curve=end (7 h); (d) close-up of Soret band of spectra in figure c; (e) haemichrome and haemochrome reference spectra: fully-recorded spectrum, black curve: metHb (8 µM) in phosphate buffer (pH 7), red curve: addition of SDS (16:1) to metHb irreversible haemichrome, blue curve: addition of Na 2 S 2 O 4 to haemichrome haemochrome. (f) close-up of Q-band region of spectra in figure E; (g) ferryHb autoreduction over 15 h: oxidation reaction of metHb (80 µM) by H 2 O 2 (800 µM) in phosphate buffer (pH 7), black curve: ferrylHb (start = 0 h), red curve: ferrylHb decay (end = 15 h); (h) addition of Na 2 S 2 O 4 to solution after 15 h haemochrome; (i) the formation of ferryHb by H 2 O 2 , continuously generated by glucose oxidase, and autoreduction of ferryHb over 3 h leading to haemichrome (prove by conversion to haemochrome): fullyrecorded spectrum: oxidation reaction of metHb (8 µM), glucose oxidase (0.6 µg/mL)/D-glucose (0.8 mM) system in phosphate buffer (pH 7), black curve: metHb (start = 0 h), red curve: ferrylHb formation and decay (end = 3 h); blue curve: addition of Na 2 S 2 O 4 to solution after 3 h haemochrome; (j) close-up of Q-band region of spectra in figure I ; (K) the formation of ferryHb by H 2 O 2 over 2 minutes, addition of catalase, 60 min of reaction, addition of Na 2 S 2 O 4 leading mainly to deoxyHb; (k) fully-recorded spectrum: oxidation reaction of metHb (8 µM) by H 2 O 2 (80 µM) in phosphate buffer (pH 7), black curve: metHb (start = 0 h), red curve: ferrylHb formation (2 min), blue curve: end of autoreduction (62 min), pink curve: addition of Na 2 S 2 O 4 to solution after 62 min mainly deoxyHb; (l) close-up of Q-band region of spectra in figure K. 
